Transurban Group’s Update on WestConnex motorway

Transurban - Kalkine Media

Acquisition of WestConnex motorway: Transurban Group’s (ASX: TCL) stock rose 0.628% to A$12.025 on August 9, 2018 (before market close) after ACCC commenced consultation on a proposed undertaking offered by TCL for the acquisition of the majority interest in the WestConnex motorway. TCL is the lead member of the Sydney Transport Partners consortium that has applied for acquisition. As per the proposed undertaking, TCL has agreed to publish detailed toll traffic data for all toll roads in New South Wales in which the company holds an interest. This data is considered to be more detailed and accurate than data that is currently available or has been shared with the bidders for WestConnex. Previously, the ACCC had raised preliminary competition concerns regarding TCL having an advantage in obtaining future toll road concessions because of having access to detailed traffic data from existing toll roads.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Meanwhile, TCL has offered to the ACCC, an undertaking that the company will publish 15-minute-interval toll gantry data each quarter, including vehicle count, vehicle classification (e.g. light vehicle, heavy vehicle) and direction of traffic flow. ACCC is still considering whether the undertaking is required and adequate to address any competition concerns regarding acquisition of WestConnex motorway. ACCC’s final decision is expected to come by 6 September 2018, but the ACCC can take an earlier decision if possible. On the other hand, TCL for FY 18 has more than doubled the full year net profit to $485 million, due to an increase in toll prices and higher vehicle numbers. The average daily traffic rose to 2.2 per cent, which led to the growth of the company’s revenue by 20.7 per cent to $3.298 billion. The company will maintain FY19 distribution guidance of 59.0 cps in the event of a successful WestConnex bid.

latest image !

FY 18 Financial Performance (Source: Company Reports)

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report